The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA's Current Position on Peptides Explained Holt Law BPC 157: The peptide with big claims and scant evidence STAT FDA Unapproved Drugs: The $7.5 Billion 505(b)(2) Opportunity Most Pharma Execs Are Ignoring DrugPatentWatch Transform Data into Market Domination